With the known delays in the NHS for diagnosis of PCOS in many patients using the current TVUS for AFC, implementing the faster alternative Elecsys AMH immunoassay may not only provide cost benefits, but also reduce waiting times for diagnosis and treatment and lead to improved patient health outcomes. This evidence concerns the gene AMH and polycystic ovary syndrome.